The most read stories from across Cardiovascular News in June 2022 include highlights from TVT 2022 (The Structural Heart Summit, 8–10 June, Chicago, USA), an interview with the creator of the first transcatheter aortic valve, a new treatment to reduce stroke and heart attack deaths and data from the UK TAVI trial.
- “TAVI was my baby, now it is a teenager”
Henning Rud Andersen (Aarhus, Denmark) tells Cardiovascular News about the development of the first device for transcatheter aortic valve implantation (TAVI), and his battle to bring the new device to market.
- Meta-analysis reveals “global collateral damage” of pandemic on cardiovascular care
A study has revealed the “global collateral damage” caused by disruption to cardiac services caused by the COVID-19 pandemic. Writing in European Heart Journal, researchers warn that problem with heart health will “…continue to accrue unless mitigation strategies are speedily implemented”.
- TVT 2022: Late-breaking data point to favourable haemodynamic performance of latest-generation TAVI device
TAVI with the Acurate neo2 (Boston Scientific) device was associated with a lower prevalence of moderate or severe paravalvular aortic regurgitation (AR) and more patients with no or trace paravalvular AR compared to an earlier-generation device—a difference that was particularly evident in patients with heavy aortic valve calcification.
- DCB in PCI: Adjunctive therapy or standard of care
This educational supplement, sponsored by Medtronic, explores the science underpinning the use of drug coated balloons (DCB) in percutaneous coronary intervention (PCI), including looking at emerging indications and diving into the important considerations when using these devices.
- TVT 2022: EXPAND registry shows benefit of MitraClip in patients outside of COAPT trial criteria
Analysis of the EXPAND registry, looking at one-year outcomes of MitraClip (Abbott) treatment in secondary mitral regurgitation (MR) patients who fall outside of the eligibility criteria of the COAPT trial has found that these patients experience “significant and durable” reductions in MR, and similar one-year clinical outcomes compared to COAPT-like patients.
- NICE recommends new treatment to reduce stroke and heart attack deaths
The National Institute for Health and Care Excellence (NICE) has recommended the use of Vazkepa (icosapent ethyl; Amarin) in adult statin-treated patients at high cardiovascular risk who have elevated triglycerides and established cardiovascular disease.
- New consensus statement will take into account latest clinical trial evidence on renal denervation
A new consensus statement—in development from the European Society of Cardiology (ESC) and the European Association of Cardiovascular Interventions (EAPCI)—will take into account latest evidence from sham controlled trials of the safety and efficacy of renal denervation as a device-based treatment for hypertension.
- UK-wide randomised trial reports non-inferiority of TAVI to SAVR for all-cause mortality at one year
TAVI was found to be non-inferior to surgery for all-cause mortality at one year among patients aged 70 years or older with severe, symptomatic aortic stenosis and moderately increased operative risk according to findings of the UK TAVI trial, published in the Journal of the American Medical Association (JAMA).
- TVT 2022: New data “debunk idea that patients with pacemakers may not be eligible for TEER”
Data from the first report on patients with a pacemaker lead across the tricuspid valve have shown that the implant of the TriClip and TriClip G4 transcatheter edge-to-edge repair (TEER) systems (Abbott) significantly reduces tricuspid regurgitation (TR) and improves quality of life.
- TVT 2022: DAPT after Watchman FLX LAAO is comparable to currently approved regimens
Dual antiplatelet therapy (DAPT) after left atrial appendage occlusion (LAAO) using the Watchman FLX (Boston Scientific) device was comparable in terms of rates of death, stroke, bleeding or device-related thrombus when compared to use of aspirin with an anticoagulant, warfarin or direct oral anticoagulant (DOAC), analysis of registry data has shown.